ACE OncoCast

The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.

ACE OncoCast is a education podcast hosted by ACE Oncology, with 50 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

ACE Oncology hosts ACE OncoCast, a education show with 50 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #4

  Expert Interview of Dr Carballo: The Role of Radiotherapy for MIBC Patients

  Nov 15, 20255 minS12

  <p><b>Natalia Carballo, MD<br/></b>Sanitas Hospitals/Atrys Health<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies.</p><...

  ListenShow Notes
• 

  Episode #3

  Expert Interview of Dr Guerrero: Optimal Management for NMIBC and MIBC Patients from a Surgical Perspective

  Nov 15, 202517 minS12

  <p><b>Félix Guerrero-Ramos, MD, PhD, FEBU<br/></b>Hospital Doce de Octubre<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of d...

  ListenShow Notes
• 

  Episode #2

  Expert Interview of Dr Real: Molecular Pathology and Biology of Urothelial Cancer

  Nov 15, 202511 minS12

  <p><b>Francisco X. Real, MD, PhD<br/></b>National Cancer Research Center<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different...

  ListenShow Notes
• 

  Episode #1

  Expert Interview of Dr Enrique Grande: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer

  Nov 15, 202520 minS12

  <p><b>Enrique Grande, MD, MSc, PhD</b> <br/>Quirónsalud Madrid<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors (ICI) and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. </p><...

  ListenShow Notes
• 

  Episode #2

  Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2)

  Nov 7, 20244 minS11

  <p><b>Natalia Carballo, MD<br/></b>MD Anderson Cancer Center Madrid<br/>Madrid, Spain</p><p>The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations...

  ListenShow Notes

Recent guests on ACE OncoCast. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.